European urology
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617.
Heidi Fettke, Louise Kostos, Maria Docanto, Patricia Bukczynska, Nicole Ng, Elizabeth Medhurst, Miyah Awad, James P Buteau, Sebastián C Eliceiry, Sathya Manoharan, Siavash Foroughi, Jason Steen, Tu Nguyen-Dumont, Michael S Hofman, Arun A Azad
Published: 202510.1016/j.eururo.2025.08.015
Abstract
BACKGROUND AND OBJECTIVE: The prostate-specific membrane antigen (PSMA)-targeted radioligand [177Lu]Lu-PSMA-617 is an approved treatment for metastatic castration-resistant prostate cancer (mCRPC). However, identification of genomic biomarkers associ…
Preview only. Read the full abstract at the source